PEG-uricase in the management of treatment-resistant gout and hyperuricemia

This publication has 57 references indexed in Scilit:

• Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout
  Arthritis & Rheumatism, 2007
• Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome
  Hypertension, 2007
• Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long‐term urate‐lowering therapy: A prospective study
  Arthritis Care & Research, 2006
• Gout and the risk of acute myocardial infarction
  Arthritis & Rheumatism, 2006
• Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network
  Journal of Clinical Oncology, 2005
• Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial
  Leukemia, 2004
• Management of Acute and Chronic Gouty Arthritis
  Drugs, 2004
• Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase
  International Journal of Immunopharmacology, 1985
• FATAL STEVENS-JOHNSON SYNDROME IN A PATIENT ON CAPTOPRIL AND ALLOPURINOL
  The Lancet, 1984
• Uricolytic Activity of Purified Uricase in Two Human Beings
  Science, 1957